Spain

In mid-May 2018, the Andalusian Agency for Health Technology Evaluation, AETSA, has published a structured summary on 18F-FDG PET in the early diagnosis of degenerative diseases of the central nervous system.

In late April 2018, AETSA, the Andalusian Agency for Health Technology Assessment, has published a report with the update of evidence regarding prognostic genomic tests in early breast cancer in Spain.

In mid-April 2018, the Basque HTA body (OSTEBA) has published recommendations of the clinical practice guidelines and use of the immunological faecal occult blood test for patients with symptoms compatible with colorectal cancer.

In mid-April 2018, the Galician HTA body, Avalia-T, has published a rapid evaluation report on screening of fetal trisomies 21, 18 and 13 by non-invasive prenatal testing. The report was done within EUnetHTA framework.

At the beginning of 2018, IACS, Institute of Health Sciences in Aragon Autonomous Community, has released a clinical practice guideline on the detection and management of Chronic Kidney Disease.

In January 2018, the Spanish Network of Technology and Services Evaluation Agencies of the National Health System (REDETS), together with the Basque regional government, has published a health technology assessment report on high intensity focused ultrasound in Tremor Essential, developed by the Basque Office for Health Technology Assessment.

In January 2018, the Galician HTA body, Avalia-T, released the technical review of The Vivistim® system, an implantable device for upper-limb rehabilitation after stroke. Evidence was found to be very limited to advice on the implementation of the technology.

On March 12th, 2018, Institute of Health Carlos III has published an evaluation report on therapeutic efficacy and safety of hyperbaric oxygen therapy for complex regional pain syndrome sympathetic reflex dystrophy.

In November 2017, the Andalusian Agency for Health Technology Assessment (AETSA) published an evaluation report (assessed within literature review) on the utility of exome sequencing for diagnosed dysmorphic syndromes.

Plasmapheresis procedure has not been supported for application in patients with Alzheimer’s by Spanish Health Technology Assessment Agency (AETS) due to insufficient evidence.

The Andalusian Agency for Health Technology Assessment (AETSA) performed evaluation of transcranial Doppler ultrasonography in patients with acute ischemic stroke. Available evidence was considered as insufficient for formulation of final conclusion. However, AETSA prepared recommendations for evidence generation strategy for this procedure.

The Basque Office for Health Technology Assessment (OSTEBA) published results of assessments of home telemonitoring on patients with heart failure. This intervention was considered as effective and cost-effectiveness technology. However, further research is needed to specify criteria for better application.